IP Library Patent Application 11167145
Patent Application
App. No. 11/167,145

Solution phase synthesis of oligonucleotides

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/167,145
Abstract

A process for the synthesis in solution phase of a phosphorothioate triester is provided. The process comprises the solution phase coupling of an H-phosphonate with an alcohol in the presence of a coupling agent to form an H-phosphonate diester. The H-phosphonate diester is oxidised in situ with a sulfur transfer agent to produce the phosphorothioate triester. Preferably, the H-phosphonate and alcohol are protected nucleosides or oligonucleotides. Oligonucleotide H-phosphonates which can be used in the formation of phosphorothioate triesters are also provided.

Claims (21)

1 - 13 . (canceled)

14 . A process for introducing a group of formula —S-A into an H-phosphonate diester moiety, comprising: reacting a substrate comprising an H-phosphonate diester moiety with a sulfur transfer agent selected from the group consisting of

a) compounds of formula:

wherein A represents an aryl, methyl, substituted alkyl or alkenyl group;

b) compounds of formula:

wherein A represents an aryl, methyl, substituted alkyl or alkenyl group; and

c) compounds of formula:

wherein A represents a methyl or alkenyl group.

15 . A process according to claim 14 , wherein the sulfur transfer agent is selected from the group consisting of

16 . A process according to claim 14 or claim 15 , wherein the H-phosphonate diester is an oligonucleotide H-phosphonate diester.

17 . A process according to claim 16 , wherein the oligonucleotide H-phosphonate diester is a protected oligonucleotide H-phosphonate diester.

18 . A process according to claim 17 , further comprising one or more subsequent deprotection steps, thereby producing a deprotected oligonucleotide.

19 . A process for the preparation of an oligonucleotide, an oligonucleotide phosphorothioate or a mixed oligonucleotide/oligonucleotide phosphorothioate, said process comprising: introducing a group of formula —S-A into an H-phosphonate diester moiety by the process according to claim 14 .

20 . A process according to claim 19 , wherein the sulphur transfer agent is selected from the group consisting of

21 . A compound of formula:

wherein A represents an aryl, methyl, substituted alkyl or alkenyl group.

22 . A compound according to claim 21 , wherein A represents a phenyl group or a —CH 2 CH 2 AN group.

23 . A compound according to claim 22 , wherein A represents a phenyl group and the phenyl group is unsubstituted or is substituted by a halo or alkyl group.

24 . A compound of formula:

25 . A compound of formula:

wherein A represents an alkenyl group.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2007
From: AVECIA LIMITED
To: AVECIA BIOTECHNOLOGY INC.
Reel/Frame 019444/0412 →